Diplomat offers LONSURF for colorectal cancer patients

Diplomat Pharmacy Inc. yesterday announced it is now offering the LONSURF (trifluridine and tipiracil) combination tablet, which recently received U.S. Food and Drug Administration approval for the treatment of refractory metastatic colorectal cancer (mCRC).

"We are focused on current treatment of those with unmet needs for colorectal cancer," Diplomat President Gary Kadlec said. "We are proud to be one of the pharmacies having LONSURF available to physicians as a new treatment option for patients."

Colorectal cancer is the third-most common type of cancer and is the second-leading cause of cancer-related deaths in the United States. There were approximately 136,830 U.S. patients diagnosed with cancer of the colon or rectum in 2014, and in 2012 there were approximately 1.1 million individuals with colorectal cancer.

LONSURF is indicated for the treatment of patients with mCRC who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-Vascular endothelial growth factor biological therapy.

Diplomat focuses on medication management programs for people with complex chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, HIV, specialized infusion therapy and other serious or long-term conditions.